The combination of carmustine wafers and temozolomide for the treatment of malignant gliomas. A comprehensive review of the rationale and clinical experience

Journal of Neuro-Oncology

Volumn 113, Issue 2, 2013, Pages 163-174

  Gutenberg, A ^a   Lumenta, C B ^b   Braunsdorf, W E K ^c   Sabel, M ^d   Mehdorn, H M ^e   Westphal, M ^f   Giese, A ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c Hospital Magdeburg   (Germany)

^d HEINRICH HEINE UNIVERSITY   (Germany)

^e UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^f UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

BCNU wafer; Glioblastoma; Malignant glioma; Multimodal therapy; Temozolomide

Indexed keywords

CARMUSTINE; CORTICOSTEROID; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PLACEBO; TEMOZOLOMIDE; ANTINEOPLASTIC AGENT; DACARBAZINE;

ABSCESS; ADJUVANT THERAPY; BONE MARROW SUPPRESSION; BRAIN ABSCESS; BRAIN CYST; BRAIN EDEMA; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RESISTANCE; CANCER SURGERY; CLINICAL PRACTICE; CLINICAL PROTOCOL; CYST; DEEP VEIN THROMBOSIS; DRUG CYTOTOXICITY; DRUG DOSAGE FORM; DRUG EFFICACY; DRUG IMPLANTATION; DRUG MEGADOSE; DRUG SAFETY; GASTROINTESTINAL SYMPTOM; GLIOBLASTOMA; HEALING IMPAIRMENT; HUMAN; INTRACRANIAL HYPERTENSION; LEUKOPENIA; LIQUORRHEA; LUNG EMBOLISM; MULTIMODALITY CANCER THERAPY; OVERALL SURVIVAL; POSTOPERATIVE CARE; PRACTICE GUIDELINE; PROSPECTIVE STUDY; PROTEIN DEPLETION; RETROSPECTIVE STUDY; REVIEW; SEIZURE; THROMBOCYTOPENIA; THROMBOEMBOLISM; WAFER; ANALOGS AND DERIVATIVES; BRAIN NEOPLASMS; CLINICAL TRIAL (TOPIC); GLIOMA; PROGNOSIS;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; CARMUSTINE; CLINICAL TRIALS AS TOPIC; DACARBAZINE; GLIOMA; HUMANS; PROGNOSIS;

EID: 84879089654     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-013-1110-x     Document Type: Review

References (67)

1. National Comprehensive Cancer Network: NCCN clinical practice guidelines in oncology. Central nervous system cancer, Version 1.2012
2. Stupp R, Tonn JC, Brada M, Pentheroudakis G (2010) High-grade malignant glioma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 21(Suppl 5):v190-v193
3. Stummer W, Pichlmeier U, Meinel T et al (2006) Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol 7:392-401
4. Brem H, Piantadosi S, Burger PC et al (1995) Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The polymer-brain tumor treatment group. Lancet 345:1008-1012
5. Westphal M, Hilt DC, Bortey E et al (2003) A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro Oncol 5:79-88
6. Stupp R, Hegi ME, Mason WP et al (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5 year analysis of the EORTC-NCIC trial. Lancet Oncol 10:459-466
7. Stupp R, Mason WP, van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987-996
8. Westphal M, Ram Z, Riddle V, Hilt D, Bortey E (2006) Gliadel wafer in initial surgery for malignant glioma: long-term follow-up of a multicenter controlled trial. Acta Neurochir (Wien) 148:269-275
9. Sampath P, Brem H (1998) Implantable slow-release chemotherapeutic polymers for the treatment of malignant brain tumors. Cancer Control 5:130-137
10. Fleming AB, Saltzman WM (2002) Pharmacokinetics of the carmustine implant. Clin Pharmacokinet 41:403-419
11. Affronti ML, Heery CR, Herndon JE 2nd et al (2009) Overall survival of newly diagnosed glioblastoma patients receiving carmustine wafers followed by radiation and concurrent temozolomide plus rotational multiagent chemotherapy. Cancer 115:3501-3511
12. Miglierini P, Bouchekoua M, Rousseau B et al (2012) Impact of the per-operatory application of GLIADEL wafers (BCNU, carmustine) in combination with temozolomide and radiotherapy in patients with glioblastoma multiforme: efficacy and toxicity. Clin Neurol Neurosurg 114(9):1222-1225
13. McGirt MJ, Than KD, Weingart JD et al (2009) Gliadel (BCNU) wafer plus concomitant temozolomide therapy after primary resection of glioblastoma multiforme. J Neurosurg 110:583-588
14. Pan E, Mitchell SB, Tsai JS (2008) A retrospective study of the safety of BCNU wafers with concurrent temozolomide and radiotherapy and adjuvant temozolomide for newly diagnosed glioblastoma patients. J Neurooncol 88:353-357
15. Salvati M, D'Elia A, Frati A et al (2011) Safety and feasibility of the adjunct of local chemotherapy with biodegradable carmustine (BCNU) wafers to the standard multimodal approach to high grade gliomas at first diagnosis. J Neurosurg Sci 55:1-6
16. Noel G, Schott R, Froelich S et al (2012) Retrospective comparison of chemoradiotherapy followed by adjuvant chemotherapy, with or without prior gliadel implantation (carmustine) after initial surgery in patients with newly diagnosed high-grade gliomas. Int J Radiat Oncol Biol Phys 82:749-755
17. Menei P, Metellus P, Parot-Schinkel E et al (2010) Biodegradable carmustine wafers (Gliadel) alone or in combination with chemoradiotherapy: the French experience. Ann Surg Oncol 17:1740-1746
18. Lechapt-Zalcman E, Levallet G, Dugue AE et al (2012) O(6)-methylguanine- DNA methyltransferase (MGMT) promoter methylation and low MGMT-encoded protein expression as prognostic markers in glioblastoma patients treated with biodegradable carmustine wafer implants after initial surgery followed by radiotherapy with concomitant and adjuvant temozolomide. Cancer 118:4545-4554
19. Gururangan S, Cokgor L, Rich JN et al (2001) Phase I study of Gliadel wafers plus temozolomide in adults with recurrent supratentorial high-grade gliomas. Neuro Oncol 3:246-250
20. Bock HC, Puchner MJ, Lohmann F et al (2010) First-line treatment of malignant glioma with carmustine implants followed by concomitant radiochemotherapy: a multicenter experience. Neurosurg Rev 33:441-449
21. McPherson CM, Gerena-Lewis M, Breneman JC, Warnick RE (2012) Results of phase I study of a multi-modality treatment for newly diagnosed glioblastoma multiforme using local implantation of concurrent BCNU wafers and permanent I-125 seeds followed by fractionated radiation and temozolomide chemotherapy. J Neurooncol 108:521-525
22. Ryken T (2011) Prospective multi-modality therapy for newly diagnosed glioblastoma with surgical resection, implantable BCNU chemotherapy and combination radiotherapy and temozolomide: long-term follow-up. Presented at the society for neuro-oncology 16th annual scientific meeting orange county, CA, USA, November 17-20, 2011 [Abstract OT-03]
23. ® Wafer) plus adjuvant and concomitant temozolomide in combination with radiotherapy in primary glioblastoma patients. Presented at the society for neuro-oncology 16th annual scientific meeting orange county, CA, USA, November 17-20, 2011 [Abstract NO-24]
24. La Rocca RV, Vitaz TW, Villaneuver W et al (2008) A Phase 2 study of multimodal therapy with surgery, carmustine (BCNU) wafer, radiation, and temozolomide in patients with newly diagnosed supratentorial malignant glioma. Abstract and poster presentation at the 8th meeting of the European association of neurooncology (EANO), Barcelona, Spain, 12-14 September, 2008 [Abstract and Poster P172]
25. Thompson D, Lazio B, Lee S et al (2010) Retrospective review evaluating safety and survival of surgery, gliadel, radiation and temozolomide for glioblastoma multiforme. Presented at the American association of neurological surgeons annual meeting, Philadelphia, PA, USA, May 1-5, 2010 [Abstract 64831]
26. Bota D, Taylor S (2006) Retrospective analysis of temozolomide (TMZ) plus BCNU wafers and TMZ alone in the primary treatment of glioblastoma multiforme. J Clin Oncol 24:3644-3650
27. Asher A (2007) Prospective analysis of temozolomide as adjuvant to Gliadel and radiation in newly diagnosed malignant glioma. Presented at the Annual Meeting of the American Association of Neurological Surgeons, Washington [Abstract 42860]
28. Rezazadeh A, La Rocca RV, Vitaz TW et al (2011) A phase II study of multimodal therapy employing surgery, carmustine (BCNU) wafer, concomitant temozolmide and radiation, followed by dose dense therapy with temozolomide plus bevacizumab for newly diagnosed glioblastoma (GBM. Presented at the society for neuro-oncology 16th annual scientific meeting Orange County, CA, USA, November 17-20, 2011 [Abstract OT-22]
29. Ewelt C, Schroeteler J, Stummer W et al (2008) Therapeutic efficacy and toxicity of local (Gliadel Wafer) and systemic intensified chemotherapy 1 Week on/1 Week off in recurrent gliomas after surgical resection [abstract O05]. Neuro Oncol 10:1061-1149
30. Yung WK, Albright RE, Olson J et al (2000) A phase II study of temozolomide versus procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer 83:588-593
31. Hart MG, Grant R, Garside R et al (2008) Temozolomide for high grade glioma. Cochrane Database Syst Rev: CD007415
32. Stummer W, van den Bent MJ, Westphal M (2011) Cytoreductive surgery of glioblastoma as the key to successful adjuvant therapies: new arguments in an old discussion. Acta Neurochir (Wien) 153:1211-1218
33. Hegi ME, Diserens AC, Gorlia T et al (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352:997-1003
34. Brandes AA, Tosoni A, Amista P et al (2004) How effective is BCNU in recurrent glioblastoma in the modern era? A phase II trial. Neurology 63:1281-1284
35. Liu L, Gerson SL (2006) Targeted modulation of MGMT: clinical implications. Clin Cancer Res 12:328-331
36. Chang CH, Horton J, Schoenfeld D et al (1983) Comparison of postoperative radiotherapy and combined postoperative radiotherapy and chemotherapy in the multidisciplinary management of malignant gliomas. A joint radiation therapy oncology group and eastern cooperative oncology group study. Cancer 52:997-1007
37. Walker MD, Green SB, Byar DP et al (1980) Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl J Med 303:1323-1329
38. Valtonen S, Timonen U, Toivanen P et al (1997) Interstitial chemotherapy with carmustine-loaded polymers for high-grade gliomas: a randomized double-blind study. Neurosurgery 41:44-48
39. Meldorf M, Riddle V, Agarwal S, Patel D (2003) Long-term efficacy of the Gliadel wafer in patients with glioblastoma multiforme. Presented at the Annual Meeting of American Association of Neurological Surgeons, San Diego, CA, USA, April 26, May 1 [Abstract 17769]
40. Roos WP, Batista LF, Naumann SC et al (2007) Apoptosis in malignant glioma cells triggered by the temozolomide-induced DNA lesion O6-methylguanine. Oncogene 26:186-197
41. Sarkaria JN, Kitange GJ, James CD et al (2008) Mechanisms of chemoresistance to alkylating agents in malignant glioma. Clin Cancer Res 14:2900-2908
42. Sariban E, Kohn KW, Zlotogorski C et al (1987) DNA cross-linking responses of human malignant glioma cell strains to chloroethylnitrosoureas, cisplatin, and diaziquone. Cancer Res 47:3988-3994
43. Plowman J, Waud WR, Koutsoukos AD et al (1994) Preclinical antitumor activity of temozolomide in mice: efficacy against human brain tumor xenografts and synergism with 1,3-bis(2-chloroethyl)-1-nitrosourea. Cancer Res 54:3793-3799
44. Batista LF, Roos WP, Christmann M, Menck CF, Kaina B (2007) Differential sensitivity of malignant glioma cells to methylating and chloroethylating anticancer drugs: p53 determines the switch by regulating xpc, ddb2, and DNA double-strand breaks. Cancer Res 67:11886-11895
45. Bocangel DB, Finkelstein S, Schold SC et al (2002) Multifaceted resistance of gliomas to temozolomide. Clin Cancer Res 8:2725-2734
46. Happold C, Roth P, Wick W et al (2012) Distinct molecular mechanisms of acquired resistance to temozolomide in glioblastoma cells. J Neurochem. doi: 10.1111/j.1471-4159.2012.07781
47. Esteller M, Garcia-Foncillas J, Andion E et al (2000) Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 343:1350-1354
48. Metellus P, Coulibaly B, Nanni I et al (2009) Prognostic impact of O6-methylguanine-DNA methyltransferase silencing in patients with recurrent glioblastoma multiforme who undergo surgery and carmustine wafer implantation: a prospective patient cohort. Cancer 115:4783-4794
49. Wick W, Platten M, Weller M (2009) New (alternative) temozolomide regimens for the treatment of glioma. Neuro Oncol 11:69-79
50. Quinn JA, Jiang SX, Carter J et al (2009) Phase II trial of Gliadel plus O6-benzylguanine in adults with recurrent glioblastoma multiforme. Clin Cancer Res 15:106-1068
51. Quinn JA, Jiang SX, Reardon DA et al (2009) Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma. J Clin Oncol 27:1262-1267
52. Gilbert MR, Wang M, Aldape KD et al (2011) RTOG 0525: a randomized phase III trial comparing standard adjuvant temozolomide (TMZ) with a dose-dense (dd) schedule in newly diagnosed glioblastoma (GBM). J Clin Oncol 29(Suppl): Abstract 2006
53. Prados MD, Yung WK, Fine HA et al (2004) Phase 2 study of BCNU and temozolomide for recurrent glioblastoma multiforme: north American brain tumor consortium study. Neuro Oncol 6:33-37
54. Glas M, Happold C, Rieger J et al (2009) Long-term survival of patients with glioblastoma treated with radiotherapy and lomustine plus temozolomide. J Clin Oncol 27:1257-1261
55. Chang SM, Prados MD, Yung WK et al (2004) Phase II study of neoadjuvant 1,3-bis(2-chloroethyl)-1-nitrosourea and temozolomide for newly diagnosed anaplastic glioma: a north American brain tumor consortium trial. Cancer 100:1712-1716
56. Rabadan AT, Hernandez D, Eleta M et al (2007) Factors related to surgical complications and their impact on the functional status in 236 open surgeries for malignant tumors in a Latino-American hospital. Surg Neurol 68:412-420
57. Sabel M, Giese A (2008) Safety profile of carmustine wafers in malignant glioma: a review of controlled trials and a decade of clinical experience. Curr Med Res Opin 24:3239-3257
58. Trinh VA, Patel SP, Hwu WJ (2009) The safety of temozolomide in the treatment of malignancies. Expert Opin Drug Saf 8:493-499
59. Dorner L, Ulmer S, Rohr A, Mehdorn HM, Nabavi A (2011) Space-occupying cyst development in the resection cavity of malignant gliomas following Gliadel(R) implantation-incidence, therapeutic strategies, and outcome. J Clin Neurosci 18:347-351
60. Engelhard HH (2000) Tumor bed cyst formation after BCNU wafer implantation: report of two cases. Surg Neurol 53:220-224
61. McGirt MJ, Villavicencio AT, Bulsara KR, Friedman HS, Friedman AH (2002) Management of tumor bed cysts after chemotherapeutic wafer implantation. Report of four cases. J Neurosurg 96:941-945
62. Ulmer S, Spalek K, Nabavi A et al (2012) Temporal changes in magnetic resonance imaging characteristics of Gliadel wafers and of the adjacent brain parenchyma. Neuro Oncol 14:482-490
63. Giese A, Bock HC, Kantelhardt SR, Rohde V (2010) Risk management in the treatment of malignant gliomas with BCNU wafer implants. Cent Eur Neurosurg 71:199-206
64. Gallego JM, Barcia JA, Barcia-Marino C (2007) Fatal outcome related to carmustine implants in glioblastoma multiforme. Acta Neurochir (Wien) 149:261-265
65. ® Wafer [prescribing information]. Eisai Inc. Woodcliff Lake, NJ: 2010
66. Beier D, Schulz JB, Beier CP (2011) Chemoresistance of glioblastoma cancer stem cells-much more complex than expected. Mol Cancer 10:128
67. Thompson EM, Frenkel EP, Neuwelt EA (2011) The paradoxical effect of bevacizumab in the therapy of malignant gliomas. Neurology 76:87-93